OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that the commercial launch of its Multiplexed ICE COLD-PCRTM (MX-ICP) product line is scheduled in the first quarter of 2015. MX-ICP is an ultra-high sensitivity DNA amplification technology that allows the simultaneous detection of multiple mutations in multiple genes from either tumor or liquid samples, such as blood or urine, on all platforms.
Multiplexed ICE COLD-PCR delivers major advantages compared to current sequencing technologies used on their own. It delivers at least a 100-fold improvement in sensitivity, detecting previously unknown genetic alterations along with those that are already known. Its ultra-high sensitivity makes it feasible to conduct comprehensive genomic analyses using either tissue or liquid biopsies, by accurately analyzing cell-free tumor DNA circulating in the blood or other bodily fluids. Importantly, MX-ICP is platform agnostic--it works on all the sequencing platforms found in labs today, greatly enhancing the sensitivity of next-generation sequencing, Digital PCR, Sanger, and other platforms. MX-ICP is easy to use, is highly reliable and is easily implemented, requiring minimal disruption to current sequencing processes or procedures.
Help employers find you! Check out all the jobs and post your resume.
Multiplexed ICE COLD-PCR delivers major advantages compared to current sequencing technologies used on their own. It delivers at least a 100-fold improvement in sensitivity, detecting previously unknown genetic alterations along with those that are already known. Its ultra-high sensitivity makes it feasible to conduct comprehensive genomic analyses using either tissue or liquid biopsies, by accurately analyzing cell-free tumor DNA circulating in the blood or other bodily fluids. Importantly, MX-ICP is platform agnostic--it works on all the sequencing platforms found in labs today, greatly enhancing the sensitivity of next-generation sequencing, Digital PCR, Sanger, and other platforms. MX-ICP is easy to use, is highly reliable and is easily implemented, requiring minimal disruption to current sequencing processes or procedures.
Help employers find you! Check out all the jobs and post your resume.
